To comment about our products, contact us at 1-855-888-2467.
The Afaxys Group Purchasing Organization (GPO) has joined forces with Bayer to form a partnership to help serve public health customers by providing Skyla and Mirena at a discounted price.
The ABC Alliance for Public Health continues the Afaxys mission to help serve women in the public health sector
Registered members of the Afaxys GPO will have access to two Bayer IUDs — Skyla® and Mirena® — at discounted prices, so together we can help provide more options to appropriate women
Only registered members of the Afaxys GPO will be guaranteed a cap on 340B/PHS pricing
And you, as a public health consumer, will have priority access to these new ABC Alliance discounts
JOIN OUR PARTNERSHIP TODAY.
PROVIDE MORE OPTIONS FOR WOMEN TOMORROW.
Request an application via email to ABCalliance@Afaxys.com
Once Afaxys receives your email, an application and membership agreement will be sent back to you
Please allow 72 hours for your application to be reviewed and processed
If you are accepted, Bayer will be notified to update their systems. You can expect to be able to begin receiving discounted pricing 7 – 10 business days after Bayer has been notified
Once you fully execute the member agreement you will be granted purchasing capability at significantly discounted rates
340B product is ordered through Bayer Direct: 877-229-3750, email@example.com
FOR THE FIRST TIME, WHETHER YOU ARE A 340B OR NON-340B PUBLIC HEALTH PROVIDER, YOU WILL HAVE ACCESS TO SKYLA AND MIRENA AT A DISCOUNTED PRICE. WE WILL OFFER DISCOUNTS OFF CURRENT PRICE POINTS ON BAYER IUDS WHILE YOUR REIMBURSEMENT PROCESS REMAINS THE SAME.
Indication for Skyla® (levonorgestrel-releasing intrauterine system) 13.5 mg Skyla is indicated for the prevention of pregnancy for up to 3 years. Skyla should be replaced after 3 years if continued use is desired. Indications for Mirena® (levonorgestrel-releasing intrauterine system) 52 mg Mirena is indicated for intrauterine contraception for up to 5 years. Mirena is also indicated to treat heavy menstrual bleeding in women who choose to use intrauterine contraception as their method of contraception. Mirena is recommended for women who have had a child. Mirena should be replaced after 5 years if continued use is desired.
WHO IS NOT APPROPRIATE FOR SKYLA AND MIRENA
Use of Skyla or Mirena is contraindicated in women with: known or suspected pregnancy and cannot be used for post-coital contraception; congenital or acquired uterine anomaly, including fibroids if they distort the uterine cavity; known or suspected breast cancer or other progestin-sensitive cancer, now or in the past; known or suspected uterine or cervical neoplasia; liver disease, including tumors; untreated acute cervicitis or vaginitis, including lower genital tract infections (eg, bacterial vaginosis) until infection is controlled; postpartum endometritis or infected abortion in the past 3 months; unexplained uterine bleeding; current IUD; acute pelvic inflammatory disease (PID) or history of PID (except with later intrauterine pregnancy); conditions increasing susceptibility to pelvic infection; or hypersensitivity to any component of Skyla or Mirena.
Use Skyla or Mirena with caution after careful assessment in patients withcoagulopathy or taking anticoagulants; migraine, focal migraine with asymmetrical visual loss, or other symptoms indicating transient cerebral ischemia; exceptionally severe headache; marked increase of blood pressure; or severe arterial disease such as stroke or myocardial infarction. Consider removing the intrauterine system if these or the following arise during use: uterine or cervical malignancy or jaundice. If Skyla or Mirena is displaced (e.g., expelled or perforated the uterus), remove it. In addition, Skyla can be safely scanned with MRI only under specific conditions.
If pregnancy should occur with Skyla or Mirena in place, remove the intrauterine system because leaving it in place may increase the risk of spontaneous abortion and preterm labor. Removal or manipulation may result in pregnancy loss. Evaluate women for ectopic pregnancy because the likelihood of a pregnancy being ectopic is increased with Skyla or Mirena. Tell women about the signs of ectopic pregnancy and associated risks, including loss of fertility. Women with a history of ectopic pregnancy, tubal surgery, or pelvic infection carry a higher risk of ectopic pregnancy.
IUDs have been associated with an increased risk of PID, most likely due to organisms being introduced into the uterus during insertion. Inform women about the possibility of PID and that PID can cause tubal damage leading to ectopic pregnancy or infertility, or infrequently can necessitate hysterectomy, or cause death. PID is often associated with sexually transmitted infections (STIs); Skyla and Mirena do not protect against STIs, including HIV.
In clinical trials with:
Skyla – PID occurred more frequently within the first year and most often within the first month after insertion.
Mirena – upper genital infections, including PID, occurred more frequently within the first year. In a clinical trial with other IUDs and a clinical trial with an IUD similar to Mirena, the highest rate occurred within the first month after insertion.
Spotting and irregular or heavy bleeding may occur during the first 3 to 6 months. Periods may become shorter and/or lighter thereafter. Cycles may remain irregular, become infrequent, or even cease. Consider pregnancy if menstruation does not occur within 6 weeks of the onset of previous menstruation.
Some serious complications with IUDs like Skyla and Mirena are expulsion, sepsis, and perforation. Perforation may reduce contraceptive efficacy. The risk of perforation is higher if inserted in lactating women and may be higher if inserted in women who are postpartum or when the uterus is fixed retroverted.
Ovarian cysts may occur and are generally asymptomatic, but may be accompanied by pelvic pain or dyspareunia. Evaluate persistent enlarged ovarian cysts.
In clinical trials with:
Skyla – the most common adverse reactions (≥5% users) were vulvovaginitis (20.2%), abdominal/pelvic pain (18.9%), acne/seborrhea (15.0%), ovarian cyst (13.2%), headache (12.4%), dysmenorrhea (8.6%), breast pain/discomfort (8.6%), increased bleeding (7.8%), and nausea (5.5%).
Mirena – adverse reactions reported in ≥5% of users were alterations of menstrual bleeding patterns [including unscheduled uterine bleeding (31.9%), decreased uterine bleeding (23.4%), and increased uterine bleeding (11.9%)], abdominal/pelvic pain (16.3%), genital discharge (14.9%), vulvovaginitis (10.5%), breast pain (8.5%), back pain (7.9%), benign ovarian cyst and associated complications (7.5%), acne (6.8%), dysmenorrhea (6.4%), and depression depressive mood (6.4%).
Teach patients to recognize and immediately report signs or symptoms of the aforementioned conditions. Evaluate patients 4 to 6 weeks after insertion of Skyla or Mirena and then yearly or more often if clinically indicated.